|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||87.87 - 88.88|
|52 Week Range||66.72 - 92.97|
|PE Ratio (TTM)||12.16|
|Dividend & Yield||3.30 (3.47%)|
|1y Target Est||N/A|
The U.S. Food and Drug Administration on Friday approved a new oral blood-thinner made by Portola Pharmaceuticals Inc to prevent deep vein thrombosis and pulmonary embolisms in acutely ill patients who are not undergoing surgery. The news sent Portola's shares up as much as 51 percent to $57.90. The drug, BevyxXa, known also as betrixaban, is the first oral treatment and first extended duration treatment for this patient population, the company said.
Forecasts for global sales of pharmaceuticals have declined for the first time in a decade as continuing pressure on prices in the key U.S. market has caused analysts to moderate revenue expectations, according to a report on Tuesday. Evaluate Pharma, which compiles consensus numbers based on analysts' forecasts, said worldwide drug sales were now expected to hit $1.06 trillion in 2022, down from $1.12 trillion predicted a year ago for the same period. It is the first time in 10 years that total drug sales have failed to beat the previous year's forecast level.
Global sales projections for the pharmaceuticals industry have been cut by a closely watched forecaster amid signs rampant drug price inflation in the US is starting to ease after years of public pressure. ...